---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000021"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:21:47.158498+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics reports FY2023 net loss $35.2M; cash boosted by $6M private placement

## Summary
- Net loss of $35.2M for FY2023 vs $28.2M in FY2022; diluted EPS -$6.96 vs -$89.27 (reverse-merger impact).
- Cash and cash equivalents $12.9M at Dec 31, 2023; $6.0M private placement closed in March 2024.
- ELI-002 2P Phase 1a data in Nature Medicine: 84% T cell response, 24% biomarker clearance, median RFS 16.33 months.
- Phase 2 randomized trial of ELI-002 7P in PDAC started; enrollment expected to complete Q4 2024.
- Initial clinical data from ELI-002 7P Phase 1 trial anticipated in Q2 2024.

## SEC filing metadata
- accession: 0001601485-24-000021
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000021/0001601485-24-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000021/angn-20240329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000021
- JSON: https://secwatch.observer/filing/0001601485-24-000021.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000021.txt

## Key facts
- Earnings Releases
  Elicio Therapeutics, Inc. reported the year ending December 31, 2023 results: net income Net loss for 2023 was $35.2 million, EPS Net loss per share for 2023 was $6.96.
  - Period: the year ending December 31, 2023
  - Net income: Net loss for 2023 was $35.2 million
  - EPS: Net loss per share for 2023 was $6.96
  - Result: reported results
  source text: Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2023 and provided corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000021/0001601485-24-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.